| Literature DB >> 27199693 |
Petra Fischer1, José P Ossandón2, Johannes Keyser2, Alessandro Gulberti3, Niklas Wilming4, Wolfgang Hamel5, Johannes Köppen5, Carsten Buhmann6, Manfred Westphal5, Christian Gerloff6, Christian K E Moll3, Andreas K Engel3, Peter König4.
Abstract
In contrast to its well-established role in alleviating skeleto-motor symptoms in Parkinson's disease, little is known about the impact of deep brain stimulation (DBS) of the subthalamic nucleus (STN) on oculomotor control and attention. Eye-tracking data of 17 patients with left-hemibody symptom onset was compared with 17 age-matched control subjects. Free-viewing of natural images was assessed without stimulation as baseline and during bilateral DBS. To examine the involvement of ventral STN territories in oculomotion and spatial attention, we employed unilateral stimulation via the left and right ventralmost contacts respectively. When DBS was off, patients showed shorter saccades and a rightward viewing bias compared with controls. Bilateral stimulation in therapeutic settings improved saccadic hypometria but not the visuospatial bias. At a group level, unilateral ventral stimulation yielded no consistent effects. However, the evaluation of electrode position within normalized MNI coordinate space revealed that the extent of early exploration bias correlated with the precise stimulation site within the left subthalamic area. These results suggest that oculomotor impairments "but not higher-level exploration patterns" are effectively ameliorable by DBS in therapeutic settings. Our findings highlight the relevance of the STN topography in selecting contacts for chronic stimulation especially upon appearance of visuospatial attention deficits.Entities:
Keywords: basal ganglia; deep brain stimulation; neglect; oculomotor control; subthalamic nucleus; unilateral stimulation; viewing bias; visual attention
Year: 2016 PMID: 27199693 PMCID: PMC4853960 DOI: 10.3389/fnbeh.2016.00085
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Demographic information and disease history of patients (left) and age-matched control subjects (two rightmost columns).
| 1 | 32 | M | 631 | 2.0 | 0.8 | 44.0 | 25.0 | 13.0 | 6.0 | No cond | 73.3 | −10/+11, 60, 130, 2.5 V | −2/+C, 60, 130, 2.3 V | 2.8 | 1.5 | 30 | m |
| 2 | 42 | M | 567 | 7.5 | 2.1 | 40.0 | 24.0 | 47.0 | 21.5 | No cond | 54.9 | −9/−10/+C, 60, 180, 2.0 V | −1/−2/+C, 60, 180, 2.1 V | N/A | N/A | 40 | m |
| 3 | 45 | M | 1249 | 7.5 | 0.3 | N/A | N/A | 39.5 | 10.0 | No cond | 61.4 | −10/+C, 60, 130, 2.7 V | −2/+C, 60, 130, 2.3 V | 2.6 | 4.0 | 51 | f |
| 4 | 48 | F | 1082 | 12.0 | 0.8 | 34.0 | 19.0 | 34.0 | 14.0 | No cond | 66.7 | −9/+C, 60, 130, 3.8 V | −2/+C, 60, 130, 2.8 V | 2.4 | 2.0 | 51 | m |
| 5 | 49 | M | 809 | 9.0 | 2.3 | 26.0 | 7.0 | 32.0 | 7.5 | veR, veL | 77.8 | −10/+C, 60, 90, 3.2 V | −2/+C, 60, 90, 2.0 V | 2.4 | 5.0 | 53 | f |
| 6 | 53 | M | 624 | 0.0 | 0.3 | 50.0 | 17.0 | 48.0 | 35.0 | veR, veL | 53.1 | −10/+C, 60, 130, 2.7 V | −2/+C, 60, 130, 2.7 V | 1.4 | 2.8 | 53 | m |
| 7 | 58 | F | 1341 | 12.0 | 2.0 | 67.0 | 10.0 | 14.5 | 14.5 | No cond | 93.8 | −10/+C, 60, 150, 2.6 V | −2/+C, 60, 150, 2.5 V | 0.8 | 1.6 | 54 | m |
| 8 | 58 | M | 1203 | 20.5 | 3.0 | 54.0 | 10.0 | 22.5 | 18.5 | No cond | 45.2 | −9/−10/+C, 60, 130, 3.0 V | −1/−2/+C, 60, 130, 3.3 V | 3.4 | 4.3 | 54 | f |
| 9 | 60 | M | 1027 | 19.8 | 3.8 | 57.0 | 17.0 | 45.5 | 24.5 | All cond | 60.9 | −8/+C, 60, 160, 2.0 V | −1/+C, 60, 160, 2.4 V | 2.5 | 2.9 | 56 | f |
| 10 | 60 | F | 967 | 22.5 | 5.8 | N/A | N/A | 46.5 | 46.5 | All cond | 47.2 | −10/+C, 90, 130, 3.9 V | −1/+C, 60, 130, 3.6 V | N/A | N/A | 56 | m |
| 11 | 60 | F | 1038 | 8.5 | 1.8 | 39.0 | 6.0 | 42.0 | 42.0 | No cond | 65.4 | −10/+9, 90, 130, 3.2 V | −2/+C, 60, 130, 2.0 V | 2.8 | 1.4 | 57 | f |
| 12 | 60 | M | 550 | 10.0 | 3.2 | N/A | N/A | 55.0 | 27.0 | veR, veL | 55.3 | −9/+C, 60, 180, 4.0 V | −1/+C, 60, 180, 4.5 V | 3.2 | 2.4 | 61 | m |
| 13 | 62 | M | 926 | 11.5 | 1.3 | 51.0 | 44.0 | 52.0 | 23.0 | No cond | 53.9 | −10/+C, 60, 160, 3.7 V | −2/+C, 60, 160, 3.5 V | 1.6 | 3.2 | 63 | m |
| 14 | 65 | M | 566 | 16.7 | 3.0 | 15.0 | 9.0 | 25.0 | 9.5 | No cond | 75.6 | −10/−9/+C, 60, 130, 3.9 V | −1/+C, 60, 130, 1.5 V | 3.2 | 3.2 | 68 | f |
| 15 | 69 | F | 508 | 15.2 | 0.8 | 31.0 | 17.0 | 26.0 | 23.5 | No cond | 89.5 | −10/+9, 60, 180, 2.5 V | −2/+C, 60, 180, 2.8 V | N/A | N/A | 68 | f |
| 16 | 72 | m | 1111 | 12.2 | 2.0 | 29.0 | 11.0 | 27.5 | 15.5 | No cond | 64.3 | −10/+9, 60, 130, 4.0 V | −2/+1, 60, 130, 3.5 V | 3.6 | 4.0 | 76 | f |
| 17 | 73 | m | 537 | 20.5 | 7.5 | 31.0 | 12.0 | 31.0 | 24.0 | No cond | 63.0 | −10/+C, 60, 130, 3.1 V | −2/+C, 60, 130, 3.1 V | 4.0 | 5.6 | 76 | m |
LED = Levodopa equivalent daily dose (conversion factors after Tomlinson et al. (.
Electrode positions (mm).
| 1 | −11.9 | −13.4 | −7.1 | TC, DYS | 36.8 | −1.01 | 1.1 | 10.4 | −14.0 | −7.1 | PAR, DYS | 44.3 | −0.08 | 0.0 |
| 3 | −11.9 | −14.9 | −6.9 | TMC, DA | 85.3 | 0.62 | 0.0 | 11.8 | −14.6 | −7.2 | TMC | 26.9 | −1.32 | 0.2 |
| 4 | −10.0 | −13.5 | −9.5 | DYS, TC, MO | 51.9 | −1.19 | 0.2 | 10.3 | −13.6 | −6.4 | PAR, DA | 56.8 | −0.52 | 0.2 |
| 5 | −9.4 | −14.4 | −7.3 | PAR | 71.0 | 2.42 | −0.3 | 10.6 | −15.8 | −7.1 | PAR | 58.6 | 1.97 | −0.5 |
| 6 | −11.1 | −14.1 | −6.9 | PAR | 47.5 | 0.14 | 0.2 | 11.7 | −12.2 | −8.1 | PAR | 60.6 | 0.88 | −0.2 |
| 7 | −8.4 | −14.2 | −11.0 | PAR, DA | 59.6 | 2.97 | −0.6 | 11.0 | −13.6 | −6.7 | DA | 56.2 | 3.91 | −0.2 |
| 8 | −11.9 | −12.2 | −8.1 | DYS, AUT | 54.3 | −0.50 | −0.2 | 12.1 | −14.0 | −7.6 | PAR, AUT | 51.0 | 1.32 | −0.1 |
| 9 | −10.8 | −13.8 | −11.3 | N/A | 49.6 | −1.25 | 0.8 | 9.4 | −16.6 | −8.4 | N/A | 50.0 | −1.24 | 1.1 |
| 11 | −10.2 | −15.3 | −8.4 | TC, PAR, DYS | 42.7 | −1.61 | 0.3 | 12.7 | −13.3 | −7.8 | MO, TMC | 40.3 | −2.96 | −0.7 |
| 12 | −6.0 | −15.6 | −12.6 | PAR | 80.4 | 3.60 | 0.5 | 11.0 | −10.6 | −5.9 | PAR | 76.7 | 2.36 | 0.2 |
| 13 | −10.9 | −12.8 | −6.7 | TMC, DYS, PAR, DA | 40.7 | −2.95 | 1.0 | 10.6 | −14.5 | −6.4 | TC, DA, PAR | 85.0 | 1.34 | 3.4 |
| 14 | −9.0 | −16.3 | −7.7 | PAR, DA | 79.6 | 5.64 | 0.5 | 11.9 | −14.6 | −5.2 | PAR, DA | 69.0 | 1.60 | 1.1 |
| 16 | −8.5 | −15.6 | −6.1 | AUT, PAR | 73.0 | 1.14 | 0.2 | 9.8 | −15.1 | −4.6 | AUT, PAR | 40.6 | 0.21 | −0.5 |
| 17 | N/A | N/A | N/A | N/A | 57.1 | −0.64 | −0.8 | N/A | N/A | N/A | N/A | 55.1 | −0.42 | −1.1 |
x = medio-lateral axis (+: right, −: left), y = antero-posterior axis, z = dorso-ventral axis. %Ri = % right side explored, InitB = initial bias (° visual angle, negative values are left of the midpoint), ΔSac = saccade length difference (right − left direction). Side effect (SE) abbreviations: DA = dysarthria; PAR = paresthesia; DYS = dyskinesia; TC = torticollis; TMC = tetanic muscle contractions; AUT = autonomic side effects (dizziness or lightheadedness); MO = mood change; N/A = not available. Patients were ordered by age starting with the youngest as in Table .
Figure 1(A) Scanpath of one subject in one trial, (B) fixation density map of all patients viewing this image. The yellow circle depicts the first fixation and the red circle the last one. Circle sizes illustrate fixation durations.
Figure 2Median UPDRS-III total sums, left body sums and right body sums for all four conditions. Lateralized values were derived from items 20–26. ON = DBS On, OFF = DBS OFF, veR = Ventral contact of right electrode active and left electrode off, veL = Ventral contact of left electrode active and right electrode off. Error bars denote the interquartile range. *Denotes significant differences (signed-rank test, p < 0.05).
Figure 3(A) Saccade length and (B) saccade length variability were significantly reduced in patients when compared with controls. Bilateral DBS in therapeutic settings significantly increased both measures. Error bars are 95% HDIs. *Denotes significant differences (with the 95% HDI of the difference excluding zero).
Figure 4Rightward bias of patients assessed by the median horizontal position. Negative values indicate deviations to the left, and positive values deviations to the right. *Denotes significant differences (with the 95% HDI of the difference excluding zero).
Figure 5Stimulation sites of the most ventral contacts used in the unilateral stimulation conditions. Marker colors code the amount of initial bias (° visual angle) with cool colors representing deviations to the left and warm colors deviations to the right. Stimulation sites, where increased voltage induced torticollis prior to determining the side-effects threshold, are depicted as diamond-shaped markers. The line represents the outcome of the multiple regression model, i.e., the best direction for predicting the initial bias during unilateral left stimulation. Variability of the location along the antero-posterior axis explained most of the bias variance, followed by the medio-lateral direction. Outlines of subcortical structures are based on 3D models of the ATAG Atlas (Keuken et al., 2013).